News

Filter

1 to 9 of 22 results

Hydra Biosciences and Boehringer Ingelheim collaborate on CNS research

25-04-2014

Privately-held US biopharma firm Hydra Biosciences and family-owned German drug major Boehringer Ingelheim…

Boehringer IngelheimHydra BiosciencesNeurologicalPharmaceuticalResearch

Vitae Pharma earns $14 million milestone from Boehringer Ingelheim in Alzheimer's collaboration

Vitae Pharma earns $14 million milestone from Boehringer Ingelheim in Alzheimer's collaboration

20-02-2014

US clinical-stage biotech firm Vitae Pharmaceuticals says it has earned a $14 million milestone payment…

BiotechnologyBoehringer IngelheimFinancialNeurologicalResearchVitae Pharmaceuticals

Boehringer Ingelheim initiates Phase I study with Ablynx nanobody triggering milestone payment

Boehringer Ingelheim initiates Phase I study with Ablynx nanobody triggering milestone payment

29-10-2013

Ablynx says its partner Boehringer Ingelheim has dosed the first healthy volunteers in a Phase I clinical…

AblynxBoehringer IngelheimEuropeFinancialNanobodyNeurologicalPharmaceuticalResearch

Oxford BioThera and Boehringer Ingelheim collaborate; Milestone for Heptares

29-04-2013

The UK's Oxford BioTherapeutics (OBT) and family-owned German drug major Boehringer Ingelheim have entered…

Boehringer IngelheimHeptares TherapeuticsLicensingNeurologicalOncologyOxford BioTherapeuticsPharmaceuticalResearchTakeda Pharmaceuticals

Parkinson's drug market set to reach $3.4 billion in 2016, says Visiongain

10-01-2013

The overall global market for drugs to treat Parkinson's disease will reach a value of $3.43 billion…

Addex PharmaBoehringer IngelheimdipraglurantMarkets & MarketingmavoglurantMirapexNeurologicalNovartisPharmaceutical

Leading dopamine agonists will continue to dominate Parkinson's market

19-08-2012

The leading dopamine agonists, pramipexole (Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol/BI-Sifrol,…

Boehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingMirapexNeuproNeurologicalPharmaceuticalRequipRytaryUCB

Lilly/Boehringer Ingelheim's Cymbalta now fibromyalgia market leader in USA

22-07-2012

US drug major Eli Lilly (NYSE: LLY) and German independent Boehringer Ingelheim's Cymbalta (duloxetine)…

Boehringer IngelheimCymbaltaEli LillyGlobalLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceutical

1 to 9 of 22 results

COMPANY SPOTLIGHT

Menarini

Back to top